Clinical Trial Update: Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating oleclumab (MEDI9447) in combination therapy for EGFR-mutant non-small cell lung cancer; the study is active but not recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Oleclumab (MEDI9447) (oleclumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-07-26